Article thumbnail

Sirtinol Treatment Reduces Inflammation in Human Dermal Microvascular Endothelial Cells

By Angela Orecchia, Claudia Scarponi, Francesca Di Felice, Elisa Cesarini, Simona Avitabile, Antonello Mai, Maria Luisa Mauro, Valentina Sirri, Giovanna Zambruno, Cristina Albanesi, Giorgio Camilloni and Cristina M. Failla

Abstract

Histone deacetylases (HDAC) are key enzymes in the epigenetic control of gene expression. Recently, inhibitors of class I and class II HDAC have been successfully employed for the treatment of different inflammatory diseases such as rheumatoid arthritis, colitis, airway inflammation and asthma. So far, little is known so far about a similar therapeutic effect of inhibitors specifically directed against sirtuins, the class III HDAC. In this study, we investigated the expression and localization of endogenous sirtuins in primary human dermal microvascular endothelial cells (HDMEC), a cell type playing a key role in the development and maintenance of skin inflammation. We then examined the biological activity of sirtinol, a specific sirtuin inhibitor, in HDMEC response to pro-inflammatory cytokines. We found that, even though sirtinol treatment alone affected only long-term cell proliferation, it diminishes HDMEC inflammatory responses to tumor necrosis factor (TNF)α and interleukin (IL)-1β. In fact, sirtinol significantly reduced membrane expression of adhesion molecules in TNFã- or IL-1β-stimulated cells, as well as the amount of CXCL10 and CCL2 released by HDMEC following TNFα treatment. Notably, sirtinol drastically decreased monocyte adhesion on activated HDMEC. Using selective inhibitors for Sirt1 and Sirt2, we showed a predominant involvement of Sirt1 inhibition in the modulation of adhesion molecule expression and monocyte adhesion on activated HDMEC. Finally, we demonstrated the in vivo expression of Sirt1 in the dermal vessels of normal and psoriatic skin. Altogether, these findings indicated that sirtuins may represent a promising therapeutic target for the treatment of inflammatory skin diseases characterized by a prominent microvessel involvement

Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3171404
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2010). Aging and disease: connections to sirtuins.
  2. (2005). Calorie restriction-the SIR2 connection.
  3. (2003). Chemokines, chemokine receptors and adhesion molecules on different human endothelia: discriminating the tissue-specific functions that affect leucocyte migration.
  4. (2010). Constitutively active NFkB triggers systemic TNFa-dependent inflammation and localized TNFaindependent inflammatory disease.
  5. (1985). de la Motte CA
  6. (2010). Differential regulation of proliferation, cell cycle control and gene expression in cultured human aortic and pulmonary artery endothelial cells by resveratrol.
  7. (2005). Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1.
  8. (1998). Endothelial cell adhesion molecules in inflammation and postischemic reperfusion injury.
  9. (1998). Endothelial cells from diverse tissues exhibit differences in growth and morphology.
  10. (2005). Evolutionarily conserved and nonconserved cellular localizations of human SIRT proteins.
  11. (2007). HDAC inhibitors as anti-inflammatory agents.
  12. (2003). Heterogeneity of microvascular endothelial cells isolated from human term placenta and macrovascular umbilical vein endothelial cells.
  13. (2006). Histone deacetylase inhibitor reduces monocyte adhesion to endothelium through the suppression of vascular cell adhesion molecule-1 expression.
  14. (2010). Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue.
  15. (2006). Histone hyperacetylation is associated with amelioration of experimental colitis in mice.
  16. (2001). Identification of a class of small molecule inhibitors of the sirtuin family of NADdependent deacetylases by phenotypic screening.
  17. (2007). Immune regulation by microvascular endothelial cells: directing innate and adaptive immunity, coagulation, and inflammation.
  18. (2009). Involvement of SIRT7 in reumption of rDNA transcription at the exit from mitosis.
  19. (2010). Involvement of sirtuin 1 in airway inflammation and hyperresponsiveness of allergic airway disease.
  20. (2008). Localization of mouse mitochondrial SIRT proteins: shift of SIRT3 to nucleus by co-expression with SIRT5.
  21. (2006). Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription.
  22. (2004). Modulation of NF-kB-dependent transcription and cell survival by the SIRT1 deacetylase.
  23. (2004). Nutrient availability regulates SIRT1 through a forkhead-dependent pathway.
  24. (2000). Phylogenic classification of prokaryotic and eukaryotic Sir2-like proteins.
  25. (2000). Placenta growth factor is induced in human keratinocytes during wound healing.
  26. (1993). Rapid analysis of leukocyteendothelial adhesion.
  27. (2009). Recent progress in the biology and physiology of sirtuins.
  28. (1988). Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures.
  29. (1993). Role of microvascular endothelial cells in inflammation.
  30. (2009). Role of SIRT1 in regulation of LPS- or two ethanol metabolites-induced TNF-alpha production in cultured macrophages cell lines.
  31. (2007). SIRT1 controls endothelial angiogenic functions during vascular growth.
  32. (2009). SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes.
  33. (2007). Sirt1 modulates premature senescence-like phenotype in human endothelial cells.
  34. (2006). SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents.
  35. (2007). SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase.
  36. (2010). SIRT1 promotes proliferation and prevents senescence through targeting LKB1 in primary porcine aortic endothelial cells.
  37. (2008). SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging.
  38. (2007). Sirtuin 2 inhibitors rescue a-synuclein-mediated toxicity in models of Parkinson’s disease.
  39. (2011). Sirtuins and inflammation: Friends or foes?
  40. (2011). STAT3-dependent effects of IL-22 in human keratinocytes are counterregulated by sirtuin 1 through a direct inhibition of STAT3 acetylation.
  41. (2005). Trichostatin A attenuates airway inflammation in mouse asthma model.
  42. (2003). Vascular endothelial growth factor receptor-1 is deposited in the extracellular matrix by endothelial cells and is a ligand for the a5bb1 integrin.